AWHL (Aspira Womens Health) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AWHL Aspira Womens Health Inc AWHL
38 GF Score
Price $0.39
GF Value $0.28
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Aspira Womens Health FFO per Share?

FFO per Share only applies to REITs.

AWHL
38GF Score
Aspira Womens Health Inc AWHL
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aspira Womens Health (AWHL) Overvalued in 2026?

Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued. The current stock price of $0.39 is trading 38.6% above its estimated GF Value™ of $0.28. GuruFocus considers Aspira Womens Health to be Significantly Overvalued.

Key valuation signals for AWHL:

  • FFO per Share:
  • GF Value™: $0.28 vs. price of $0.39 (38.6% above fair value)
  • GF Score™: 38/100 with 8 warning signs

No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aspira Womens Health Business Description

Address 12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
38GF Score

Get the complete analysis for AWHL

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price
$0.28
GF Value